Drugs / GSK3732394
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03984812 | Jun 2019 → Mar 2020 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3732394 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03984812 ↗ |
| Modality | Protein / enzyme biologic | “The GSK3732394 multivalent protein” PMID 36191080 ↗ Oct 2022 |
| Route | Subcutaneous | “GSK3732394 10 milligram (mg) or PBO will be administered by subcutaneous (SC) injection to the subjects.” NCT03984812 ↗ |
| Target | CD4 | “It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor.” NCT03984812 ↗ |